Home › Compound Library › Fremanezumab (Ajovy)

Fremanezumab (Ajovy)

Biologicprescriptionsubcutaneous · inferred

Humanized IgG2a monoclonal antibody targeting the CGRP ligand for migraine prevention. Two approved regimens: 225 mg SC monthly or 675 mg SC every three months (three 225 mg injections). Biphasic disposition with fast target-mediated phase (~60h) and slow linear phase (~30 days). SC bioavailability ~60%. Very favorable safety profile; main AE is injection-site reaction.

Projected serum levels — 225 mg, custom (shown daily)

Fremanezumab (Ajovy)
Fremanezumab (Ajovy) modeled serum levels, 225 mg custom (shown daily) over 121 days Population-based pharmacokinetic estimate. Steady state reached after approximately 109 days. 0 2.5k 5k 7.5k 10k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule ≈ steady state · day 109
Fremanezumab (Ajovy) modeled serum levels with a loading dose of 675 mg, then 225 mg custom (shown daily) The first dose is larger so levels approach steady state faster. 0 2.5k 5k 7.5k 10k Day 0 Day 30 Day 61 Day 91 Day 121 Time on a regular schedule

Maintenance schedule: 225 mg custom (shown daily) (subcutaneous).

Loading schedule: 675 mg on day 1, then 225 mg custom (shown daily) — reaching therapeutic levels sooner.

Modeled steady state after ~109 days: peak ≈ 7.3k mg, trough ≈ 7.3k mg body load. Population-based estimate over 121 days for a 225 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Biologic
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
31 days
Common dose
225 mg
Suggested maximum
675 mg/day
Reference dose range
113–675 mg (single dose)
Suggested cadence
custom (shown daily)
Validated against
225 mg sc — Cmax 41 mg/L at 120 h

Documented interactions

  • watch
    Galcanezumab (Emgality) + Fremanezumab (Ajovy) Stacked effects

    Fremanezumab (Ajovy) and Galcanezumab (Emgality) both push the cgrp ligand in the same direction.

Serum checks 1 modeled interaction pairings for fremanezumab (ajovy) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Population pharmacokinetic modelling and analysis of fremanezumab in healthy subjects and patients with migraine Fiedler-Kelly J et al. · Clinical Pharmacokinetics, 2019 DOI

    Population PK model quantifying fremanezumab's biphasic disposition, ~30-day terminal half-life, and supporting monthly and quarterly dosing.

  2. Fremanezumab for the preventive treatment of chronic migraine Silberstein SD et al. · New England Journal of Medicine, 2017 DOI

    Pivotal phase 3 HALO-CM trial showing fremanezumab 225 mg monthly and 675 mg quarterly reduced headache days in chronic migraine.

2 published studies referenced in the app, each with a plain-language summary.